The Follicular Lymphoma Global Patient Survey 2026 has now closed. Thank you to everyone who shared their experiences and helped strengthen the patient voice in research, education and support.
To mark Blood Cancer Awareness Month, FLF has launched new diagnosis resources and a patient-informed video to help people better understand follicular lymphoma and navigate the challenges of diagnosis.
FL Voices, is the Follicular Lymphoma Foundation’s flexible patient involvement network. Share your experiences, shape research, and make a difference.
On 9th March came the announcement that tazemetostat (Tazverik) is being voluntarily withdrawn worldwide. Ipsen, the company that markets tazemetostat, made this decision after new safety findings emerged from the ongoing SYMPHONY 1 clinical trial, which indicated a possible increased risk of secondary blood cancers when the drug was used in a specific combination regimen (lenalidomide and rituximab, also referred to as R2).
NICE has approved epcoritamab (Tepkinly) on the NHS for adults in England, Wales and Northern Ireland with relapsed or refractory follicular lymphoma after two prior treatments. The decision introduces a new bispecific antibody therapy option for patients with limited treatment choices.
In February 2026, the Follicular Lymphoma Foundation and the Josep Carreras Leukaemia Research Institute convened a global Scientific Conclave in Barcelona to confront the barriers slowing progress toward cures for follicular lymphoma. Over three days, leading experts aligned around clear priorities and a coordinated strategy designed to turn insight into decisive action for patients.
In 2025 the FLF accelerated scientific momentum, strengthened global collaboration, and elevated the patient voice. In her first year as Global CEO, Emma France reflects on the turning points that pushed progress from possibility into action and shares how the FL community is shaping a future where cures become achievable.
The Follicular Lymphoma Foundation at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, one of the world’s premier gatherings for groundbreaking hematology research.
On November 18, 2025, the FDA approved epcoritamab-bysp (EPKINLY®) in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma after at least one prior therapy. This approval applies to patients in the United States..
The Unlock the Cure Gala 2025 brought supporters together to fund vital research and deliver hope for people living with follicular lymphoma.
We are thrilled to announce that the FLF will be taking centre stage at the upcoming 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, from June 17th-21st, 2025.
The Mark Foundation for Cancer Research and the Follicular Lymphoma Foundation have joined forces to co-fund two new ASPIRE Awards focused on developing more personalized treatment strategies for FL.
The FLF welcomes Emma France as our new Global CEO. With over 20 years of non-profit leadership, Emma will help drive our mission forward with bold action and impactful change.
“Treat the person, not just the disease.”
World Cancer Day is on the 4th February. This year’s theme, United by Unique, emphasizes an essential shift in cancer care: putting patients at the heart of every decision.
This year has been transformative, marked by groundbreaking progress in our mission to cure follicular lymphoma.
We are thrilled to announce that our Unlock the Cure Gala Dinner saw us raise an astounding £800,000 to further our mission of finding a cure for follicular lymphoma.
Our webinars are free, interactive, and designed to empower everyone affected by FL. Register today and stay informed on these important discussions.
Every 3 minutes, someone in the U.S. is diagnosed with blood cancer. Blood Cancer Awareness Month highlights leukemia, lymphoma, and myeloma.
This strategic alliance with LLS and IFLI will further accelerate pioneering research and help cure follicular lymphoma through our Research United to CURE FL program.
We are thrilled to announce that this remarkable event saw us raise an astounding £500,000 to further our mission of finding a cure for follicular lymphoma.
The FLF will be attending the prestigious 65th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego this December.
The panel addressed the crucial topic of “Accelerating the Impact of the Cancer Mission Five-Fold” moderated by IQVIA Institutes Executive Director.
Our partnership with LLS continues with the second cycle of the “LLS-FLF United to CURE FL Awards”. This strategic alliance will further accelerate pioneering research and help cure follicular lymphoma.
The FLF joins forces with The Leukemia & Lymphoma Society to bring hope to those living with follicular lymphoma. The partnership marks a significant milestone in accelerating leading edge research.
In just the last six months, we have made tangible progress in advancing research, raising awareness, and working closely with patients.
On May 18th, the FLF hosted our very first webinar called “An Overview of Follicular Lymphoma: What You Need to Know.”
We’re thrilled to share a big step forward in our fight against follicular lymphoma. In April of this year, our founder, Nicola Mendelsohn, officially opened the new branch of the Follicular Lymphoma Foundation in Israel.
The Follicular Lymphoma Foundation (FLF) proudly hosted its first international FL Summit, titled “Joining Forces to Cure Follicular Lymphoma,” in Tel Aviv, Israel. The summit,
New funding of $2 million for research to get one step closer to a cure for Follicular Lymphoma. Our mission at the FLF is to
Henry and Esther Shirman, two supporters that have been with the FLF since day one, recently celebrated their 50th wedding anniversary, and they certainly did
The wonderful Snowdown Colliery Welfare Brass Band recently (October 8th) created a fabulous afternoon of music for the local community of Dover, Kent. The band
